Home › Funds › DEERFIELD MANAGEMENT COMPANY, L.P. › NAMS

DEERFIELD MANAGEMENT COMPANY, L.P. position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

DEERFIELD MANAGEMENT COMPANY, L.P. reported holding 4,264,789 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$144.5M, representing 1.81% of its reported portfolio and ranking #13 among its reported holdings. DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed NAMS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)4.26M sh
Reported value held$144.53M
Portfolio Weight1.81%
First reportedQ1 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DEERFIELD MANAGEMENT COMPANY, L.P.'s NAMS position evolved

DEERFIELD MANAGEMENT COMPANY, L.P. first disclosed a stake in NAMS in Q1 2024 at 667,000 shares (US$15.8M). The position peaked in Q4 2025 at 4,164,789 shares, worth US$146.1M. Across 10 filings, DEERFIELD MANAGEMENT COMPANY, L.P. increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 4,264,789 shares valued at US$144.5M. Notable position changes include a 30% increase in Q2 2024 (shares fell 10% over the following quarter), a 378% increase in Q4 2024 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 667.00K $15.77M New
Q2 2024 869.25K $16.70M Add
Q3 2024 901.75K $14.97M Add
Q4 2024 4.31M $110.88M Add
Q1 2025 4.10M $84.01M Reduce
Q2 2025 5.12M $92.65M Add
Q3 2025 4.27M $121.34M Reduce
Q4 2025 4.16M $146.10M Reduce
Q1 2026 4.26M $136.52M Add
Q2 2026 4.26M $144.53M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has DEERFIELD MANAGEMENT COMPANY, L.P. held NAMS?

DEERFIELD MANAGEMENT COMPANY, L.P. has disclosed NAMS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is DEERFIELD MANAGEMENT COMPANY, L.P.'s current position in NAMS?

As of Q2 2026, DEERFIELD MANAGEMENT COMPANY, L.P. holds 4.26M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $144.53M, representing 1.81% of its reported portfolio and ranking #13.

Has DEERFIELD MANAGEMENT COMPANY, L.P. been buying or selling NAMS?

In the latest 13F filing (Q2 2026), DEERFIELD MANAGEMENT COMPANY, L.P. held unchanged its position in NAMS. The position peaked in Q4 2025 at 4.16M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.